Solid Tumour Oncology
Precise killing of intracellular proteins differentially expressed in tumours
Immune Reset
Cell-specific depletion of populations responsible for autoimmunity
Targeted payload delivery
Precise delivery of payloads to specific, hard-to-target cell types via antigen presentation
Rapid validation on your priority targets. We deliver AI-designed, lab-validated candidate molecules.
Open new biologic frontiers. We help you discover and validate novel targets in your disease areas.
Share the journey from novel target to clinic. Your disease expertise, our platform capabilities.
We are developing a pipeline of first-in-class protein therapeutics for development or licensing.
Direct access to our model suite for your discovery programs.
Memorial Sloan Kettering Co-development
Synteny Announces Drug Development Collaboration with Leading Global Cancer Center to Advance Next-Generation TCR-Based Therapeutics
AI for Science Compute Award to Train Sovereign Probabilistic World Model
Synteny Awarded Largest Allocation in UKRI AIRR ‘AI for Science’ Programme to Build a Sovereign Probabilistic World Model for Goal-Directed Immunological Discovery
Lilly ExploR&D
Synteny is working with Lilly ExploR&D to optimise the developability of Synteny’s pan-KRAS TCR T cell engager